Corvus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Corvus Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
6.8%
Earnings growth rate
21.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -69.9% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Corvus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -27 | 7 | 17 |
30 Sep 23 | 0 | -30 | 7 | 17 |
30 Jun 23 | 0 | -39 | 7 | 23 |
31 Mar 23 | 0 | -41 | 7 | 24 |
31 Dec 22 | 0 | -41 | 8 | 24 |
30 Sep 22 | 0 | -41 | 8 | 25 |
30 Jun 22 | 0 | -37 | 8 | 22 |
31 Mar 22 | 0 | -40 | 8 | 26 |
31 Dec 21 | 0 | -43 | 9 | 29 |
30 Sep 21 | 0 | -7 | 10 | 32 |
30 Jun 21 | 0 | -6 | 11 | 31 |
31 Mar 21 | 0 | -5 | 12 | 30 |
31 Dec 20 | 0 | -6 | 12 | 32 |
30 Sep 20 | 0 | -44 | 12 | 34 |
30 Jun 20 | 0 | -46 | 11 | 36 |
31 Mar 20 | 0 | -48 | 11 | 39 |
31 Dec 19 | 0 | -47 | 11 | 38 |
30 Sep 19 | 0 | -46 | 11 | 37 |
30 Jun 19 | 0 | -46 | 11 | 37 |
31 Mar 19 | 0 | -44 | 11 | 36 |
31 Dec 18 | 0 | -47 | 11 | 39 |
30 Sep 18 | 0 | -48 | 10 | 40 |
30 Jun 18 | 0 | -51 | 10 | 42 |
31 Mar 18 | 0 | -54 | 10 | 45 |
31 Dec 17 | 0 | -56 | 10 | 46 |
30 Sep 17 | 0 | -55 | 10 | 46 |
30 Jun 17 | 0 | -52 | 10 | 43 |
31 Mar 17 | 0 | -46 | 9 | 37 |
31 Dec 16 | 0 | -36 | 8 | 29 |
30 Sep 16 | 0 | -31 | 7 | 24 |
30 Jun 16 | 0 | -24 | 5 | 19 |
31 Mar 16 | 0 | -36 | 4 | 14 |
31 Dec 15 | 0 | -31 | 2 | 11 |
30 Sep 15 | 0 | -25 | 1 | 6 |
Quality Earnings: C17 is currently unprofitable.
Growing Profit Margin: C17 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: C17 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare C17's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: C17 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: C17 has a negative Return on Equity (-69.87%), as it is currently unprofitable.